A groundbreaking study has unveiled a surprising connection between a protein long implicated in amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, and fundamental cellular processes that could explain links to both cancer and dementia. Researchers at Houston Methodist Research Institute have shown that TAR DNA-binding protein 43 (TDP-43), a hallmark of ALS pathology, plays a critical role in regulating DNA mismatch repair (MMR), the cellular machinery responsible for correcting errors during DNA replication.

This discovery, detailed in a recent publication in Nucleic Acids Research, reveals that imbalances in TDP-43 levels—too low or too high—disrupt MMR gene expression, leading to genome instability. In neurons, this manifests as damage contributing to neurodegeneration in ALS and frontotemporal dementia (FTD). In cancer cells, elevated TDP-43 correlates with higher mutation burdens, potentially fueling tumor progression.

Unraveling ALS: A Progressive Neurodegenerative Disease

Amyotrophic lateral sclerosis (ALS) is a relentless neurodegenerative disorder that targets motor neurons, the nerve cells responsible for controlling voluntary muscles. Patients experience progressive muscle weakness, paralysis, and eventually respiratory failure, with most succumbing within 2-5 years of diagnosis. Globally, ALS affects approximately 222,000 people, with an incidence of about 1.9 per 100,000 individuals annually. In the United States alone, prevalence has risen to around 33,000 cases as of 2022, projected to reach 36,000 by 2030 due to aging populations and improved survival rates from therapies like riluzole and edaravone.

While 90-95% of cases are sporadic, genetic factors play a role in familial forms. TDP-43 pathology is present in nearly 97% of ALS cases, where the protein mislocalizes from the nucleus to the cytoplasm, forming toxic aggregates that impair cellular function. Discovered in 2006 as the primary component of ubiquitinated inclusions in ALS and FTD brains, TDP-43 has since been central to understanding these diseases.

TDP-43: From RNA Splicing to DNA Guardian

TDP-43, or TAR DNA-binding protein 43 kDa, is primarily known as an RNA-binding protein involved in alternative splicing, mRNA stability, and transport. Under normal conditions, it resides in the nucleus, binding to UG-rich sequences to regulate thousands of transcripts essential for neuronal health. However, in ALS and FTD, hyperphosphorylated and ubiquitinated TDP-43 forms cytoplasmic inclusions, depleting nuclear levels and disrupting gene expression.

The new research expands TDP-43's repertoire, demonstrating its direct influence on DNA mismatch repair genes. MMR corrects base-pair mismatches and small insertion/deletion loops arising during DNA replication, preventing mutations. Key MMR proteins include MutS homologs (MSH2, MSH6) for mismatch recognition and MutL homologs (MLH1, PMS2) for repair execution. Defects in MMR underlie Lynch syndrome, responsible for 2-4% of colorectal cancers and associated with microsatellite instability (MSI-high) tumors.

The Mechanism: TDP-43's Grip on MMR Gene Splicing

Lead investigator Muralidhar L. Hegde, Ph.D., and colleagues found that TDP-43 selectively modulates MMR gene expression through alternative splicing. Depletion or overexpression of TDP-43 alters splicing of MLH1 and MSH6, leading to dysregulated protein levels. In cellular models, TDP-43 knockdown increased mutation rates, while overexpression hyperactivated repair, causing excessive DNA incisions and strand breaks—toxic to post-mitotic neurons.

• TDP-43 binds promoter-proximal regions of MMR genes, influencing transcript variants.
• Low nuclear TDP-43 (as in ALS) fails to suppress erroneous splicing, impairing repair efficiency.
• High TDP-43 (observed in some tumors) overstimulates MMR components, promoting futile repair cycles and genomic chaos.

Cancer database analyses (e.g., TCGA) confirmed positive correlations between TDP-43 expression, MMR gene upregulation, and tumor mutation burden (TMB). For instance, in breast and lung cancers, elevated TDP-43 links to higher somatic mutations.Read the full study in Nucleic Acids Research.

Bridging Neurodegeneration: ALS, FTD, and DNA Damage

Frontotemporal dementia (FTD), the second most common dementia under age 65, overlaps with ALS in 10-15% of cases. TDP-43 inclusions define FTLD-TDP pathology in ~50% of FTD. Genome instability from faulty MMR exacerbates neuronal vulnerability: unrepaired DNA damage triggers apoptosis or dysfunctional proteostasis, accelerating motor neuron loss in ALS and cortical atrophy in FTD.

Historical evidence supports DNA repair defects in ALS; FUS and C9orf72 mutations also impair non-homologous end joining. This TDP-43 finding unifies mechanisms, suggesting shared pathways vulnerable to environmental genotoxins like pesticides.

Cancer Connections: TDP-43 as a Double-Edged Sword

Paradoxically, while TDP-43 loss harms neurons, its upregulation in cancers drives oncogenesis. Studies show TDP-43 overexpression in hepatocellular carcinoma, breast cancer, and glioblastoma promotes epithelial-mesenchymal transition (EMT), invasion, and chemoresistance. The Houston Methodist team posits that hyperactive MMR under high TDP-43 generates replication stress, elevating TMB and neoantigens—potentially exploitable for immunotherapy but risky for metastasis.

In Lynch syndrome carriers (pathogenic MMR variants, ~1:280 prevalence), lifetime CRC risk reaches 50-80%. TDP-43 dysregulation may mimic or exacerbate such defects, broadening therapeutic targets.

Experimental Evidence: From Cells to Insights

The study employed CRISPR-edited cell lines, iPSC-derived neurons, and patient tissues. TDP-43 modulation via siRNA or overexpression plasmids shifted MMR efficiency, measured by mutation reporter assays and comet assays for DNA breaks. Partial rescue by inhibiting overactive MSH6 confirmed causality. Collaborators from MD Anderson and UT Southwestern validated findings across models.

Therapeutic Horizons: Targeting TDP-43 and MMR

"This tells us that the biology of this protein is broader than just ALS or FTD... puts it at the intersection of two of the most important disease categories," says Hegde. Early 2026 saw Dewpoint Therapeutics nominate a TDP-43 condensate modulator for ALS trials, aiming to restore nuclear localization. Antibodies targeting toxic aggregates reduced propagation in preclinical models.

MMR modulation offers promise: PARP inhibitors for deficient repair, or MSH6 knockdown for hyperactive states. Clinical trials could repurpose Lynch syndrome drugs for neurodegeneration.Houston Methodist research overview.

The Research Landscape and Collaborations

Houston Methodist's Center for Neuroregeneration leads with NIH funding. Multi-institutional efforts, including MD Anderson for cancer angles, highlight academia's role. Similar findings in FUS-linked ALS reinforce DNA repair as a therapeutic nexus.

Future Outlook: Unified Disease Models

This TDP-43 revelation heralds precision medicine: biomarkers for risk stratification, gene therapies for splicing correction. As ALS prevalence climbs 25% by 2040, such insights are urgent. Academic researchers worldwide are poised to translate these findings, bridging neurodegeneration and oncology.ScienceDaily coverage.

Stakeholders—from patients to policymakers—should prioritize funding for TDP-43 trials. Actionable steps include genetic screening for at-risk families and lifestyle measures to minimize DNA damage, like antioxidant-rich diets.

Photo by National Cancer Institute on Unsplash